ViewRay upgraded by Morgan Stanley
$VRAY
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Morgan Stanley upgraded ViewRay from Underweight to Equal-Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2023 | $4.00 → $1.00 | Buy → Neutral | B. Riley Securities |
| 4/17/2023 | $7.00 → $1.25 | Buy → Hold | Jefferies |
| 4/14/2023 | Outperform → Perform | Oppenheimer | |
| 4/14/2023 | Buy → Neutral | BTIG Research | |
| 4/14/2023 | $7.00 → $1.75 | Buy → Hold | Stifel |
| 1/25/2022 | $7.00 | Buy | Stifel |
| 1/11/2022 | $7.00 | Neutral → Buy | B. Riley Securities |
| 10/14/2021 | $7.00 | Neutral | B. Riley Securities |
4 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
3 - ViewRay, Inc. (0001597313) (Issuer)
B. Riley Securities downgraded ViewRay from Buy to Neutral and set a new price target of $1.00 from $4.00 previously
Jefferies downgraded ViewRay from Buy to Hold and set a new price target of $1.25 from $7.00 previously
Oppenheimer downgraded ViewRay from Outperform to Perform
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental
DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i
Three-time public company CFO joins NUBURU with deep experience in leading business transformation and optimization of financial processes on a global scale NUBURU®, the industry leader in high power and high brightness industrial blue lasers, today announced that it has appointed Brian Knaley as Chief Financial Officer. In this strategic role, Mr. Knaley will oversee all aspects of finance and investor relations as NUBURU accelerates and implements its growth strategy to expand the presence of its blue laser technology across target markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005131/en/Three-time public compan
NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental
DENVER, July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (NASDAQ:VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. Trading of the Company's common st
Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER, July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the "Petitions") under Chapter 11 of Title 11 the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the District of Delaware (the "Court"). The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the Company's assets, while continuing to support its customers during the Chapter 11 pro
DENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.Received 13 new orders for MRIdian systems, totaling $68.3 million.Total backlog increased to $411.0 million as of March 31, 2023, compared to approximately $331.0 million as of March 31, 2022.Cash and cash equivalents, inclusive of restricted cash, was $85.5 million as of March 31, 2023.Net l
DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars." About ViewRay® ViewRay, Inc. (NASDAQ:VRA
DENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786. The confirmation number is 56031524. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars". About ViewRay® ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MR
25-NSE - ViewRay, Inc. (0001597313) (Subject)
8-K - ViewRay, Inc. (0001597313) (Filer)
NT 10-Q - ViewRay, Inc. (0001597313) (Filer)
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock rose 36.8% to $0.1 during Tuesday's after-market session. At the close, 9 Meters Biopharma's trading volume reached 4.7 million shares. This is 1095.7% of its average volume over the last 100 days. The company's market cap stands at $1.4 million. ViewRay (NASDAQ:VRAY) stock moved upwards by 11.99% to $0.03. Trading volume for this security closed at 19.2 million, accounting for 150.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.1 million. Plus Therapeutics (NASDAQ:PSTV) stock increased by 10.36% to $2.45. The company's market cap stands at $6.1 million. PAVmed (NASDAQ:PAVM) sha
On Tuesday, 56 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS). 9 Meters Biopharma (NASDAQ:NMTR) was the smallest company by market cap to set a new 52-week low. Humanigen (NASDAQ:HGEN)'s stock came under the most pressure, trading down 73.22% to reach a new 52-week low. NeuBase Therapeutics (NASDAQ:NBSE) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. On Tuesday, the following stocks set new 52-week lows: Apellis Pharmaceuticals (NASDAQ:APLS) stock drifted down 2.25% on Tuesday morning to hi
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 45.4% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $30.6 million. Enzo Biochem (NYSE:ENZ) shares rose 16.91% to $1.59. The market value of their outstanding shares is at $79.0 million. Aravive (NASDAQ:ARAV) shares moved upwards by 14.09% to $1.7. The market value of their outstanding shares is at $101.7 million. Novan (NASDAQ:NOVN) stock increased by 11.5% to $0.14. The market value of their outstanding shares is at $3.9 million. Biotricity (NASDAQ:BTCY) stock rose 10.72% to $3.51. The market value of their outstanding shares is at $30.7 million. Alpha Tau Medical (NASDAQ:DRTS) stock move